Elsevier Publishes New Book on Developing Therapeutics for Alzheimer’s Disease

Valuable resource for researchers assesses prospects for the emergence of effective agents

Cambridge, MA, July 21, 2016

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of Developing Therapeutics for Alzheimer's Disease: Progress and Challenges, along with three other new books focused on the growing body of knowledge surrounding Alzheimer’s disease (AD).  This announcement comes in advance of the Alzheimer’s Association International Conference 2016, from July 24-27 in Toronto, Ontario, Canada, where Elsevier is exhibiting in booth # 824.

Edited by Dr. Michael Wolfe, Developing Therapeutics for Alzheimer's Disease provides a thorough overview of the latest advances towards the goal of realizing effective therapeutics for Alzheimer’s disease, along with the major hurdles that still must be overcome and the potential solutions to these problems. It outlines the special challenges related to specific targets and approaches, while presenting a realistic, comprehensive and balanced view of drug discovery and development in this area. The book primarily focuses on approaches to targeting the amyloid β-peptide and tau, but also includes chapters on neuroprotective agents, cognitive enhancers and approaches to targeting apolipoprotein E.

Dr. Wolfe is Professor of Neurology at Harvard Medical School and Brigham and Women’s Hospital. Since 1999, his work has focused on understanding the molecular basis of Alzheimer’s disease and related disorders, and identifying effective approaches for pharmacological intervention. Awards for his work include the Sato Memorial International Award in bioorganic and medicinal chemistry from the Pharmaceutical Society of Japan (2003), the MetLife Award for Biomedical Research (2008), a Zenith Fellows Award from the Alzheimer’s Association (2008), and the Potamkin Prize from the American Academy of Neurology (2009).

The four new Alzheimer’s disease books are:

In order to meet content needs in neurological science, Elsevier uses proprietary tools to identify the gaps in coverage of the topics. Editorial teams strategically fill those gaps with content written by key influencers in the field, giving students, faculty and researchers the content they need to answer challenging questions and improve outcomes. These new books, which will educate the next generation of neuroscientists and provide critical foundational content for information professionals, are key examples of how Elsevier is enabling science to drive innovation.


Note for editors
E-book review copies of the new books are available to credentialed journalists upon request. Contact Robin Hayward at r.hayward@elsevier.com.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com

Media Contact
Pam Foote
Publicity Team, Science & Technology Books, Elsevier
+1 978 691 5572